Date: 2017-01-04
Type of information: Licensing agreement
Compound: Spiegelmers technology
Company: Noxxon Pharma (Germany) Aptarion biotech (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism: spiegelmer. Spiegelmers are a variant of aptamers, which are based on DNA or RNA. They are built on a backbone of 'mirror-image' RNA or DNA - L-stereoisomers. . The L-stereochemistry gives spiegelmers high stability in biological fluids since they are not recognized by naturally occurring enzymes that degrade DNA and RNA called nucleases. Spiegelmers are also immunologically passive. They can be manufactured chemically.
Disease:
Details: * On January 4, 2017, Noxxon Pharma has announced an agreement with Aptarion biotech to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion. Noxxon has maintained exclusive rights to Spiegelmers binding to the targets of its clinical stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer®
technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies. This agreement is another step on the transition of Noxxon to a clinical-stage oncology company.
Financial terms:
Latest news:
